The Singapore Health Sciences Authority (HSA) has approved its 20-valent pneumococcal conjugate vaccine (PCV20) that protects against invasive pneumococcal disease and pneumonia caused by 20 Streptococcus pneumoniae (pneumococcus) serotypes, US pharma giant Pfizer (NYSE: PFE) announced on Saturday.
To be marketed under the brand name Appexxnar, this vaccine is approved for active immunization for individuals aged 18 years and older, advancing the company's ongoing commitment to help prevent certain potentially-serious infectious respiratory diseases.
Pfizer markets the vaccine under the Prevnar 20 name on the USA, where it was approved in January 22. The Prevnar family of vaccines generated sales of $1.7 billion in 2022 for Pfizer, down 68%.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze